Platinum based countermeasures and combinations with protective agents
Active Cooperative Agreement Awarded Last action
- Award ID
- UH3NS134957
- Recipient
-
Purdue University UEI YRXVL4JYCEF5
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $727,820
Award facts
- Assistance listing
- 93.310 Trans-NIH Research Support
- Completion date 44% complete
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- West Lafayette, IN 47907, USA
Award details come from USAspending.gov.
Description
- Abstract
- This project's primary endpoint focus will be efficiently rescuing toxic cyanide exposure using three distinct animal models. None of the current countermeasure options meet the requirements for the risk scenarios and objectives in PAR 22-209. There are continual threats of chemical exposure to human populations. Health and safety measures in the workplace cannot fully mitigate the chances of unexpected or malicious use of chemical toxicants. Safe and effective countermeasures to a cyanide chemical exposures that can deploy in a variety of challenging emergency settings represent a continual unmet medical need. In addition to survival, mitigating the sequel morbidities of toxic chemical exposures means another challenge for next-generation countermeasures. For metabolic poisons that reach high levels of exposure like cyanide, approaches to reverse the insult's effects are warranted to mitigate more prolonged-term effects. A team of investigators with experience in discovering and developing countermeasures and therapeutic agents and expertise in medicinal chemistry, pharmacology, toxicology, discovery pharmaceutics, in vivo phenotypic screens, and complimentary animal models will pursue milestones established from 3 specific aims. Aim 1: to improve and down-select next-generation platinum (II)- based countermeasure agents hydrogen cyanide scavengers with properties that meet the criteria for developability. Aim 2: to evaluate combinations of the metabolite glyoxylate with platinum (II)-based scavenger agents. Aim 3: to evaluate the efficacy and safety in a porcine model for cyanide intoxication of lead candidate platinum (II)-based agents alone and in combinations with the metabolite glyoxylate.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Beth Israel Deaconess Medical Center, Inc. | $128,366 | |
| University Of California, San Diego | $78,379 | |
| The Regents Of The University Of Colorado | $193,148 |
Quick answers
Who received award UH3NS134957?
UH3NS134957 was awarded to Purdue University by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 20, 2024.
How much is award UH3NS134957 worth?
$727,820 has been obligated on UH3NS134957.
Which agency awarded UH3NS134957?
National Institute of Neurological Disorders and Stroke (National Institutes of Health) awarded UH3NS134957, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award